Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
By
Ryan Cross
6h ago· 2 min readNews
Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup.
You might also wanna read
Anne Wojcicki Wins Bidding for 23andMe
wsj.com·11mo ago
CRISPR takes a bold leap toward silencing Down syndrome's extra chromosome
medicalxpress.com·1mo ago
Senators Investigate Pharmaceutical Companies' Direct-to-Consumer Telehealth Platforms for Steering Patients to High-Cost Drugs
U.S. senators are investigating direct-to-consumer (DTC) telehealth platforms operated by pharmaceutical companies like Eli Lilly and Pfizer
arstechnica.com·4mo agoQt45: A small polymerase ribozyme that can synthesize itself
science.org·3mo ago
Gene therapy restored hearing in deaf patients
news.ki.se·11mo ago
Anne Wojcicki's Nonprofit Acquires 23andMe for $305 Million
Anne Wojcicki's nonprofit, TTAM Research Institute, has successfully outbid Regeneron Pharmaceuticals to acquire 23andMe for $305 million, i
cnbc.com·11mo ago